LYKA LABS
|
The Current P/E Ratio of LYKA LABS is -25.66.
| Share Price | ₹66.6 | Aug 14,2026 |
| Market Cap | ₹240.9 Cr | |
| Earnings-TTM | ₹-9.4 Cr | TTM-Consolidated Results |
| Price/Earnings | -25.66x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of LYKA LABS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹240.9 Cr] as on Aug 14,2026
(/) Earnings [ ₹-9.4 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -25.66x ]
Thus, for LYKA LABS , the investors are currently willing to pay -25.66 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LYKA LABS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LYKA LABS over the last five years.
Historical PE (Price/Earnings) ratio chart of LYKA LABS
PE Ratio Performance Analysis for LYKA LABS
- LYKA LABS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 10.99x.
- LYKA LABS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LYKA LABS 's p/e ratio peaked in Mar2025 at 44.97x.
- LYKA LABS 's p/e ratio hit its five-year low in Mar2026 of 0x.
How does LYKA LABS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| LYKA LABS | -9.39 | -25.66 | 240.9 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.94 | 461,848.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 77.14 | 225,648.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 85.39 | 184,109.0 |
| CIPLA LTD | 3,364.84 | 34.81 | 117,139.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.66 | 100,328.0 |
| MANKIND PHARMA LTD | 2,055.11 | 48.63 | 99,945.0 |
| LUPIN LTD | 5,551.01 | 18.41 | 102,192.0 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.31 | 113,715.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.69 | 95,397.6 |
| LAURUS LABS LTD | 1,090.76 | 89.90 | 98,064.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LYKA LABS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -25.66x |
| Max industry PE | 89.90x |
| Median industry PE | 34.81x |
| Average industry PE | 40.84x |
You may also like the below Video Courses